
Phase 1 Study of Anitocabtagene Autoleucel for the Treatment of Patients with Relapsed and/or 4825 Refractory Multiple Myeloma (RRMM): Efficacy and Safety with 38.1-Month Median Follow-up

1. David and Etta Jonas Center for Cellular Therapy, University of Chicago, IL, USA; 2. Beth Israel Deaconess Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology and Oncology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Division of Hematology, Department of Medical School, Boston, MA, USA; 3. Divisio 6. The University of Texas MD Anderson Cancer Center, Houston, TX, USA; 7. Massachusetts General Hospital, Boston, MA, USA; 8. Medical College of Wisconsin, Milwaukee, WI, USA; 8. Medical College of Wisconsin, Milwaukee, WI, USA; 9. Arcellx, Inc., Redwood City, CA, USA; 10. Section of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, USA.

Introduction


- RRMM is characterized by progressively worse outcomes with each line of therapy¹, and novel therapies are needed to provide durable responses in laterline patients.
- While BCMA CAR T-cell therapies have demonstrated compelling clinical activity in patients with RRMM, outcomes continue to be limited particularly in patients with high-risk disease characteristics²⁻⁴.
- Anitocabtagene autoleucel (anito-cel, previously CART-ddBCMA) is an autologous D-Domain BCMA-directed chimeric antigen receptor (CAR) T-cell therapy being studied in patients with RRMM.
- The BCMA-binding D-Domain is a small, synthetic 8 kDa protein comprised of 73 amino acids that fold into a stable triple alpha-helix bundle, resulting in several key attributes described in **Figure 1**^{5,6}.
- This report presents efficacy and safety results with a median follow-up of 38.1 months from the first-in-human Phase 1 study of anito-cel in patients with 4L+ RRMM.

Figure 1: D-Domain Attributes – Non-Antibody-Derived Synthetic Protein



Methods


- First-in-human Phase 1, multi-center, dose escalation trial in 4L+ RRMM Eligibility
- At least 3 prior lines of therapy including a PI, IMiD, and anti-CD38 antibody; or triple-refractory disease following treatment with a PI, IMiD, and anti-CD38 antibody as part of the same or different regimens
- Measurable disease per at least 1 of the criteria: serum M-protein \geq 1.0 g/dL, urine M-protein ≥200 mg/24 hours; involved serum free light chain ≥100 mg/L with abnormal κ/λ ratio; >1 extramedullary lesion on imaging, including at least 1 lesion that is ≥ 1 cm and able to be followed by imaging assessments; or BMPCs ≥30%
- ECOG PS of 0 or 1 and adequate organ function
- Primary Endpoints: Incidence of TEAEs, DLTs; establish the RP2D
- Select Secondary Endpoints: BOR and ORR by IMWG Consensus Criteria¹¹
- Select Exploratory Endpoints: MRD negativity, DOR, PFS, OS
- Toxicity grading was performed per NCI CTCAE v 5.0, except for CRS and ICANS which were graded per ASTCT consensus criteria¹².
- Data cut-off: October 3, 2024
- Figure 2: Phase 1 Dose Escalation Study Design



ASTCT, American Society for Transplantation and Cellular Therapy; BMPC, bone marrow plasma cell; BOR, best overall response; CRS, cytokine release syndrome; CTCAE, Common Terminology Criteria for Adverse Events; DLT, dose-limiting toxicity; DOR, duration of response; ECOG PS, Eastern Cooperative Oncology Group Performance Status Scale; ICANS, immune effector cell-associated neurotoxicity; IMiD, immunomodulatory drug IMWG, International Myeloma Working Group; MRD, minimal residual disease; NCI, National Cancer Institute; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI, proteosome inhibitor; RP2D, recommended phase 2 dose; TEAE, treatment-emergent adverse event

<u>Michael R. Bishop, MD¹, Jacalyn Rosenblatt, MD², Binod Dhakal, MD, MS³, Noopur Raje, MD⁴, Daniella Cook, BS⁵, Mahmoud Gaballa, MD⁶, Estelle Emmanuel-Alejandro, BA⁷, Danielle Nissen, BS⁸, Kamalika Banerjee, MA⁹,</u> Rebecca J. Chan, MD, PhD⁹, Ana Kostic, MD⁹, Christopher R. Heery, MD⁹, Tim Welliver, MD, PhD⁹, David Avigan, MD², Andrzej J. Jakubowiak, MD, PhD¹⁰, and Matthew Frigault, MD, MS⁷

Results




Ó

Table 1: Patient and Disease Characteristics

Characteristics	DL1: 100 x 10 ⁶ CAR+ T cells (n=32)	DL2: 300 x 10 ⁶ CAR+ T cells (n=6)	Total (n=38)
Age, median (min - max)	66 (44 - 76)	60 (52 - 65)	66 (44 - 76)
Age ≥ 65	19 (59%)	1 (17%)	20 (53%)
Gender, male / female	18 (56%) / 14 (44%)	5 (83%) / 1 (17%)	23 (61%) / 15 (39%)
Race White Black / African American Asian Other	28 (88%) 3 (9%) 1 (3%) 0 (0%)	4 (67%) 1 (17%) 0 (0%) 1 (17%)	32 (84%) 4 (11%) 1 (3%) 1 (3%)
ECOG PS ^a 0 / 1	9 (28%) / 23 (72%)	3 (50%) / 3 (50%)	12 (32%) / 26 (68%)
High Risk Prognostic Feature ^b	20 (63%)	6 (100%)	26 (68%)
Prior Lines of Therapy, median (min - max)	5 (3 - 7)	4 (3 - 16)	4 (3 - 16)
Triple refractory	32 (100%)	6 (100%)	38 (100%)
Penta refractory	21 (66%)	5 (83%)	26 (68%)
Prior ASCT	25 (78%)	4 (67%)	29 (76%)
Time since diagnosis, median (min - max)	6.5 years (1.5 - 14.9 years)	6.9 years (1.7 - 11.0 years)	6.5 years (1.5 - 14.9 years)
Bridging therapy ^c	20 (63%)	6 (100%)	26 (68%)

a) Eastern Cooperative Oncology Group Performance Status Scale; b) Defined as a patient with EMD, ISS Stage III (B2M \geq 5.5), High Risk Cytogenetics (Del17p, t(14;16), or t(4;14)), or BMPC ≥60%; c) Bridging agents were limited only to those previously received

Figure 4: Best Overall Response Rate and MRD Negativity



■ sCR/CR ■ VGPR ■ PR

*Evaluable patients had identifiable malignant clone in the baseline bone marrow aspirate

Table 2: Kaplan-Meier Estimated PFS Rates in All Patients & High-Risk Subgroups

	All Patients	High Risk Features*	Age ≥65 years	
Patients n	38	26	20	
(%)	(100)	(68.4)	(52.6)	
12-month PFS %	75.9	72.2	85.0	
(95% CI)	(58.7, 86.6)	(50.4, 85.7)	(60.4, 94.9)	
24-month PFS %	56.6	60.2	65.0	
(95% CI)	(39.2, 70.8)	(38.7, 76.3)	(40.3, 81.5)	
30-month PFS %	50.3	60.2	53.6	
(95% CI)	(33.0, 65.3)	(38.7, 76.3)	(29.5, 72.7)	

The estimated median PFS has not been reached at 30 months for high-risk subgroups

*High Risk Features defined as a patient with EMD, ISS Stage III (B2M ≥ 5.5), High Risk Cytogenetics (DeI17p, t(14;16), or t(4;14)), or BMPC ≥60%

Figure 6: Median OS for All Patients is Not Reached Median Follow-up of 38.1 Months (Range: 25-56)




Table 3: CA CAR T-a Per AS CRS Max grade, Median onse Median dura ICANS Max grade, Median onse Median dura **Toxicity Manag** Tocilizumab Dexamethas *Median duration numbers updated due to ongoing data review Hematologic Neutropenia^a Anemia Thrombocytope Lymphopenia

Safety

Leukopenia^a Febrile neutrope

a) Grouped categor ymphopenia, leuko b) Aspartate Aminot

- risk features:

Acknowledgments

• The patients and their families • The staff, caregivers, research coordinators, and investigators at each participating institution References

1. Goel, et al. Blood Cancer J. 2023; 13:11; 2. Dima, et al. Blood 2023; 142 (Supplement 1):4882; 3. Martin, et al. J. Clin. Oncol. 2023; 41:1265-1274; 4. Ferment, et al. Br. J. Haematol. 2024; 205:990-998. 5. Rotte, et al. Immuno-Oncology Insights 2022; 3:13-24; 6. Frigault, et al. Blood Adv. 2023; 7:768-777; 7. Cante-Barrett, et al. BMC Res. Notes 2016; 9:312; 8. Buonato, et al. Mol. Cancer Ther. 2022; 21:1171-1183; 9. Zhu, et al. Proc. Nat. Acad. Sci. 2003; 100 Kumar, et al. Lancet Oncol. 2016; 17:e328-e346; 12. Lee, et al. Biol. Blood Marrow Transplant. 2019; 25:625-638; 13. Freeman, et al. Blood 2024; ASH Annual Meeting Oral Presentation. Abstract #1031

• No delayed or non-ICANS neurotoxicities have been observed at a median follow-up of 38.1 months - Including no incidence of Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome • One patient had a Grade 5 event post study treatment (unrelated cardiac arrest due to non-study drug overdose) • All secondary primary malignancies (SPMs) were required to be reported irrespective of relatedness or timing No SPMs of T cell origin occurred

- Hematologic SPMs of myelodysplastic syndrome (MDS) were reported in 3 patients as unrelated AEs by the investigator, and occurred in the setting of disease progression in patients heavily pre-treated with agents known to be associated with MDS

AR-T Associated	AEs of CR	S and ICA	NS per A	ASTCT C	riteria (N=	=38)			
ssociated AEs TCT Criteria	DL1: 100 x 10 ⁶ CAR+ T cells (n=32)			DL2: 300 x 10 ⁶ CAR+ T cells (n=6)			Total (N=38)		
	Gr1	Gr2	Gr3	Gr4	Gr1	Gr2	Gr3	Gr4	Any Gr
, n (%)	15 (47%)	15 (47%)	0 (0%)	0 (0%)	3 (50%)	2 (33%)	1 (17%)	0 (0%)	36 (95%)
set (min - max)	2 days (1 - 12 days)			2 days (1 - 2 days)					
ation* (min - max)	5 days (1 - 9 days)			5 days (3 - 9 days)					
, n (%)	Gr1	Gr2	Gr3	Gr4	Gr1	Gr2	Gr3	Gr4	Any Gr
	3 (9%)	2 (6%)	1 (3%)	0 (0%)	0 (0%)	0 (0%)	1 (17%)	0 (0%)	7 (18%)
et (min - max)	4.5 days (3 - 6 days)				7 days				
ation (min - max)	3.5 days (1 - 9 days)			17 days					
agement									
)	27 (84%)			5 (83%)			32 (84%)		
sone	20 (63%)			2 (33%)			22 (58%)		

Table 4: Grade 3/4 AEs (non-CRS/ICANS) per CTCAE v5.0 ≥5% after cell infusion (N=38)

	n (%)	Non-hematologic	n (%)
	33 (86.8%)	Hypertension	3 (7.9%)
	21 (55.3%)	Pneumonia	3 (7.9%)
enia ^a	17 (44.7%)	AST ^b increased	2 (5.3%)
	16 (42.1%)	Cardiac arrest	2 (5.3%)
	8 (21.1%)	Cellulitis	2 (5.3%)
penia	6 (15.8%)	Hypokalemia	2 (5.3%)
		Hyponatraemia	2 (5.3%)
		Hypophosphatemia	2 (5.3%)
		Pain in extremity	2 (5.3%)
ry for each of the following: neutropenia, thrombocytopenia, openia, and sepsis;		Sepsis ^a	2 (5.3%)
otransferase Test		Urinary tract infection	2 (5.3%)

Conclusions

• Anito-cel utilizes a novel, synthetic, compact and stable D-Domain binder that facilitates high transduction efficiency, CAR positivity, and CAR density on the T-cell surface. • With a median follow-up of 38.1 months, anito-cel achieved rapid, high response rates with longterm durable remissions in a refractory, heavily pre-treated population of whom 68% had high-

• ≥CR achieved in 79% of patients

• Median PFS of 30.2 months in all patients and 34.3 months in patients with \geq CR Median OS not reached

• Similar efficacy and durable remissions were observed across high-risk subgroups • The anito-cel safety profile is predictable and manageable

• No delayed or non-ICANS neurotoxicities, including no Parkinsonism, no cranial nerve palsies, and no Guillain-Barré syndrome were observed across the Phase 1 and Phase 2 (iMMagine-1)¹³ clinical trials.

• Anito-cel efficacy & safety compares favorably with available treatments for RRMM, including for RRMM bearing high-risk features.

Anito-cel is being co-developed with Kite's global cell therapy leadership

iMMagine-1 (NCT05396885) is the pivotal Phase 2 trial evaluating anito-cel in patients with RRMM and >3 prior LOT including a proteosome inhibitor, an IMiD, and an anti-CD38 monoclonal antibody

iMMagine-3 (NCT06413498) is a global, Phase 3 trial comparing anito-cel to standard of care therapy in patients with RRMM after 1-3 prior LOT, including an anti-CD38 monoclonal antibody and an IMiD